Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research Report - Global Forecast till 2030

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size, Growth and Insights by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2030

ID: MRFR/HC/6637-HCR | 95 Pages | Published By Kinjoll Dey on March 2023         

Idiopathic Pulmonary Fibrosis Treatment Market Speak to Analyst Request a Free Sample

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market

Idiopathic pulmonary fibrosis treatment market is projected to grow at 6.7% CAGR to reach USD 2200 million during the forecast period 2030

Segmentation
By Treatment Drug Class Oxygen Therapy Lung Transplant Others
Key Players
Companies Profiled   Boehringer Ingelheim GMBH   Biogen   Novartis AG   Medicinova Inc.   Bristol-Myers Squibb Company   Galapagos NV   Hoffmann-La Roche AG
Drivers
Market Driving Forces   Rising Prevalence Rates of lung diseases coupled with increasing geriatric population is anticipated to fuel the market growth
Request a Free Sample

Idiopathic Pulmonary Fibrosis Treatment Market Overview


Idiopathic pulmonary fibrosis treatment market size is expected to reach USD 2200 million by 2030 at 6.7% CAGR during the forecast period 2022-2030. The treatment for severe lung disease is known as the idiopathic treatment. Today, the prevalence of such lung infections is higher among the population. This type of condition can make the tissues in the lung hard. Further, thickened tissues can cause more damage to the body and even cause death in some.


 This chronic illness requires medical attention for reducing the hardened tissues in the lungs. Due to the prevalence of this condition the Idiopathic Pulmonary Fibrosis Treatment market is witnessing more demand. In recent years, the number of individuals seeking treatment for such illnesses is growing. The rising health awareness among individuals is causing this influence in the market. Moreover, the treatment of lung diseases has several processes. Identification, screening, imaging and much more treatments are essential.


Also, when having pulmonary fibrosis the individual's body may not get enough oxygen for crucial organs. The hardened tissues stop oxygen circulation in the body. The bloodstream may not work properly in the patients. Due to this reducing teeth, and stiffness and creating a pathway for the oxygen to pass to vital organs is essential. People between 50 to 70 years of age are the most affected. The wide range of solutions for his condition is rising overall Idiopathic Pulmonary Fibrosis Treatment Market Revenue. 


Idiopathic Pulmonary Fibrosis Treatment Market Covid analysis 


2019 is the year when covid 19 was identified as the virus that will create a global pandemic. Since then humans are suffering from the effects of this virus both physically and economically. In recent years, the cases of covid 19 are slowing down. However, the economic impact of this pandemic is high. Since the outbreak of the virus, people are witnessing symptoms such as cough, high fever, lung problems and much more.


Social distancing and exceptional treatment were provided for all the affected. It is a period that leads to the massive demand for health services. During that period other illnesses were considered less priority. However, the treatment for other chronic illnesses is resuming in hospitals. It is contributing to intensive treatment for conditions such as idiopathic pulmonary. The vulnerability to lung disease is higher after covid. In the upcoming years, more treatment will happen for patients with this illness. Idiopathic Pulmonary Fibrosis Treatment Market Research will also increase. 


Idiopathic Pulmonary Fibrosis Treatment Market dynamics 


Crucial market drivers 


The growth of the cigarette population is a crucial driver of the market. People smoking tobacco and cigarette is still growing in many regions. An individual with the habit often develops chronic lung conditions. People of age 50 to 70 years who have experience with smoking are more affected by the idiopathic pulmonary condition. The continuous rise in the smoking population is expected to drive this market in upcoming years.


The prevalence of fibrosis will also be high. The growth of the geriatric population is another driver for this market. Today, there are many above the age of 50 who experience lung conditions. Due to other health disorders and sensitive lungs, they experience ling issues. Furthermore, the rising treatment for fibrosis is another crucial driver. The research in the fibrosis market is immense.


It is leading to a massive demand for new treatments. The growing availability of treatment is leading to a high adoption rate. The health awareness among the individuals is also rising. Due to awareness among people early detection and treatment for this market are increasing. 


The market growth opportunities 


The ideal drug for the fibrous market is growing. There are lots of key players in the market who have extensive production of drugs. There are high research activities in the market that lead to effective drugs. The ideal treatment for that condition will continue to provide more growth opportunities. Favourable reimbursement police are other factors that contribute to growth.


Earlier the treatment for lung conditions does not have proper insurance and reimbursements. Due to this patients hesitate to take up fine treatment as they are expensive. With reimbursement policies, the prospects of more patients willing to undergo treatment will rise. Moreover, technological advancements in the market will contribute to growth. There are massive technological investments in the market. After covid 19 many countries are allocating more for medical technologies. It is a crucial factor that will create new opportunities in future.


Demand from the emerging economies plays a crucial for future growth. Several growing economies witness a high case of lung diseases. Due to this, there is a medical emergency to offer good treatment for patients. all this will rise fibrosis treatment in growing nations. These are factors that contribute to exceptional Idiopathic Pulmonary Fibrosis Treatment Market Growth opportunities in future. 


The market restraints 


Pulmonary Fibrosis Treatment still has less awareness among people. Some counties have fewer experts and awareness about lung disease. People developing this condition offer to recover from poor screening, imaging and treatment. This causes more mortality rate for the affected.


There is a need for effective treatment in some counties. Also, a lack of awareness is affecting the penetration of fine treatments in these regions. The unavailability of proper drugs and treatment can cause a decline in demand for the market. Also, the expansion rate of the fibrosis treatment market can reduce. 


The market challenges 


Pulmonary Fibrosis Treatments come to the expensive treatments on the market. Several counties do not offer proper insurance for such treatments. Without proper health insurance, this can be an expensive treatment. It is a treatment that includes a high range of screening and imaging.


Apart from the primary stage of treatment, the final stages are much costlier. The surgery for fibrosis and lung-related conditions is complex. due to the complexity, the cost of surgery is expensive. Most of the population with this condition does not find the treatment affordable. The adoption rate o the market can remain less due to these reasons. 


Cumulative growth analysis 


The Idiopathic Pulmonary Fibrosis Treatment Market Analysis remains positive in the forecast period. there are lots of drivers for the market that create a steady demand trend. Factors that drive demand are the growing smoking population and geriatric population. These are factors that boost demand for the treatment. However, the unavailability of treatment in some regions remains an issue.


It is declining the demand. Also, the expense of lung treatments poses a challenge to people. It is a reason that can reduce the overall expansion and adoption rate of the market. However, the market opportunities such as drug developments will create a positive influence. 


Value chain analysis 


North America is a crucial region player. it is a player that dominates with the highest Idiopathic Pulmonary Fibrosis Treatment Market Share. The treatment for this condition continues to have exceptional demand among the population. The reason for it is the high availability of drugs.


The clinical drugs for the condition are high which creates more awareness for treatment. Further, the rise of the cigarette population will stir the adoption of such treatment. In recent years the smoking population has doubled. It is a reason that causes more demand for this region. 


Idiopathic Pulmonary Fibrosis Treatment Market Segment overview 


By Drug Type Idiopathic Pulmonary Fibrosis Treatment Market



  • Nintedanib

  • Pirfenidone


By Distribution Channel Idiopathic Pulmonary Fibrosis Treatment Market



  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Providers


By Region Idiopathic Pulmonary Fibrosis Treatment Market


North America


 



  • The U.S.

  • Canada

  • Mexico


Europe



  • Spain

  • France

  • UK

  • Germany

  • Italy

  • Rest of Europe


Asia-Pacific



  • Japan

  • Australia

  • China

  • India

  • South Korea

  • Rest of Asia-Pacific


LAMEA



  • Saudi Arabia

  • South Africa

  • Brazil

  • Rest of LAMEA


Idiopathic Pulmonary Fibrosis Treatment Market Competitive landscape 


As per the Idiopathic Pulmonary Fibrosis Treatment Market Forecast, there are several strong players in the competitive landscape. Also, the entrance of new players is expected to rise.


There are more innovations in terms of drugs and treatment in the market. Also, there are acquisitions, expansions, mergers and new partnerships in the market. The rising investments and research activities will cause new launches in the market. 


Regional analysis 


Three crucial regional players in the market are Asia Pacific, Europe and North America. North America will continue to dominate the region with a high number of key players. The investments are growing in this market. Due to this need for drugs and treatment will rise for lung disease. The favourable reimbursements policies are other factors that contribute to an exceptional adoption rate.


Further, Asia pacific is the next largest market with positive Idiopathic Pulmonary Fibrosis Treatment Market Trends. The growing cases of lung diseases are expanding the demand and supply. The awareness about this condition will further widen demand. Europe is a region that will continue to have massive growth opportunities in the forecast period. 


The key players in the Idiopathic Pulmonary Fibrosis Treatment Market are

  • Bristol-Myers Squibb Company

  • AstraZeneca PLC

  • Boehringer Ingelheim

  • Hoffmann-La Roche Ltd. (Genentech, Inc.,)

  • Mission Therapeutics

  • Biogen, Inc.

  • Shionogi co Ltd

  • FibroGen, Inc.

  • GNI Group Ltd

  • Galapagos NV
  • Recent developments¬†


    The key players in North America continue to discover new treatments for fibrosis conditions. As it is a tissue-based illness the experts are launching new stem cell therapy that has the potential for an effective cure. 



    Report Scope:

    Report Attribute/Metric Details
      Market Size   USD 2200 million
      CAGR   6.7%
      Base Year   2021
      Forecast Period   2022-2030
      Historical Data   2020
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Treatment
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibrogen, Inc., Cipla, Merck & Co., Inc., Prometic Life Sciences Inc
      Key Market Opportunities   Increasing cases of IPF and growing demand for minimally invasive procedures to diagnose and treat different chronic diseases
      Key Market Drivers   Rising Prevalence Rates of lung diseases coupled with increasing geriatric population is anticipated to fuel the market growth


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The high cost of the surgery that is associated with it would hinder the market growth.

    The drug class segment would lead the market.

    The oxygen therapy segment would be the fastest growing.